Apyx Medical Corporation (NASDAQ:APYX) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Apyx Medical Corporation (NASDAQ:APYX) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $6.50.

A number of analysts have weighed in on APYX shares. Zacks Research raised shares of Apyx Medical to a “hold” rating in a report on Tuesday, July 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a report on Monday, September 21st. Maxim Group began coverage on shares of Apyx Medical in a report on Tuesday, September 29th. They issued a “buy” rating and a $6.00 price target for the company. Finally, HC Wainwright started coverage on shares of Apyx Medical in a research report on Monday, July 13th. They set a “buy” rating and a $7.00 price objective for the company.

Apyx Medical Stock Up 2.9%

APYX stock opened at $2.51 on Thursday. Apyx Medical has a twelve month low of $2.32 and a twelve month high of $5.08. The company has a current ratio of 5.68, a quick ratio of 4.53 and a debt-to-equity ratio of 3.19. The company has a market capitalization of $105.72 million, a P/E ratio of -12.55 and a beta of 1.45. The firm has a 50 day simple moving average of $2.85 and a 200-day simple moving average of $3.61.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. The company had revenue of $13.88 million during the quarter, compared to analyst estimates of $13.18 million. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.60%. On average, equities research analysts predict that Apyx Medical will post -0.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Nantahala Capital Management LLC bought a new stake in shares of Apyx Medical during the second quarter valued at approximately $14,683,414. AIGH Capital Management LLC bought a new position in Apyx Medical in the 2nd quarter worth approximately $5,066,000. BlackRock Inc. bought a new position in Apyx Medical in the 2nd quarter worth approximately $2,519,000. Sei Investments Co. grew its holdings in Apyx Medical by 298.6% in the 1st quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock worth $2,208,000 after buying an additional 448,174 shares in the last quarter. Finally, Kingsview Wealth Management LLC acquired a new stake in Apyx Medical in the 2nd quarter valued at approximately $962,000. 55.33% of the stock is owned by institutional investors and hedge funds.

About Apyx Medical

Apyx Medical Corporation (NASDAQ: APYX) is a medical technology company that develops, manufactures and markets advanced energy systems for use in surgical and aesthetic procedures. The company’s products are based primarily on its proprietary Helium Plasma technology, which combines helium gas and radiofrequency energy to deliver controlled thermal effects to soft tissue.

Its principal product platform is Renuvion, a system designed for use by physicians in soft-tissue procedures. The platform includes generators, handpieces and related accessories intended to support tissue coagulation, cutting, dissection and contraction in various surgical and aesthetic applications.